

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Zitac vet 200 mg tablets for dogs

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

#### **Active substance:**

Cimetidine 200 mg per tablet.

#### **Excipients:**

| <b>Qualitative composition of excipients and other constituents</b> |
|---------------------------------------------------------------------|
| Lactose monohydrate                                                 |
| Cellulose, microcrystalline                                         |
| Maize starch pregelatinized                                         |
| Sodium starch glycolate (type A)                                    |
| Magnesium stearate                                                  |

White, oblong tablets, scored on both sides.

### **3. CLINICAL INFORMATION**

#### **3.1 Target species**

Dogs.

#### **3.2 Indications for use for each target species**

Symptomatic treatment for the reduction of vomiting associated with chronic gastritis in dogs.

#### **3.3 Contraindications**

None.

#### **3.4 Special warnings**

Treatment with cimetidine is symptomatic only and does not result in resolution of histopathological changes associated with gastritis. It is recommended that dogs showing persistent vomiting should undergo appropriate investigations to diagnose the underlying cause before starting treatment. This is especially important in older animals. The reduction of gastric acidity caused by cimetidine may contribute to bacterial overgrowth and antigenic stimulation.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

In case of renal dysfunction, adjustment of the dose may be required as the clearance of cimetidine may be decreased. If the response to treatment is poor within 15 days, the diagnosis and treatment plan should be re-evaluated.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

None.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Dogs:

|                                                                                |                                        |
|--------------------------------------------------------------------------------|----------------------------------------|
| Very common<br>(>1 animal / 10 animals treated):                               | Mammary gland swelling <sup>1</sup>    |
| Very rare<br>(<1 animal / 10,000 animals treated, including isolated reports): | Prostate weight reduction <sup>2</sup> |

<sup>1</sup> Transient and self-resolving, slight swelling (gynaecomastia); anti-androgenic activity.

<sup>2</sup> reversible, with no impact on reproductive performances

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

#### Pregnancy and lactation:

The use of the veterinary medicinal product during pregnancy and lactation in the target species has not been investigated. Therefore, use of the veterinary medicinal product during pregnancy and lactation should be based on a risk benefit-assessment by the responsible veterinarian.

### 3.8 Interaction with other medicinal products and other forms of interaction

Due to inhibition of cytochrome P-450 activity by cimetidine, the metabolism and elimination of some drugs can be reduced. Clinically relevant interactions may occur with compounds having a narrow therapeutic index, e.g. beta-blockers, calcium channel blockers, benzodiazepines, barbiturates, phenytoin, theophylline, aminophylline, warfarin and lidocaine. Doses of such drugs may need to be reduced when administered concomitantly with cimetidine.

The increased gastric pH resulting from cimetidine administration may lead to reduced absorption of drugs requiring an acid medium for absorption. It is recommended that at least 2 hours should elapse between administration of cimetidine and aluminium or magnesium hydroxide, metoclopramide, digoxin or ketoconazole when possible.

### 3.9 Administration routes and dosage

For oral use.

Dose and route of administration: 5 mg of cimetidine per kg of bodyweight administered three times daily by the oral route (see indicative table below). The concomitant use of appropriate dietary measures is strongly recommended. In clinical trials the efficacy of cimetidine has only been studied concomitantly with a hypoallergenic diet.

Table: Number of Zitac vet 200 mg tablets to be administered three times daily according to body weight.

| Weight (kg) | Number of Zitac vet 200 mg tablets |
|-------------|------------------------------------|
| 11 to 20    | $\frac{1}{2}$                      |
| 21 to 40    | 1                                  |
| 41 to 60    | $1 \frac{1}{2}$                    |

Recommended treatment scheme: reduction of vomiting is achieved in about 2 weeks. Animals should however be treated for at least 2 weeks after the remission of clinical signs, so a minimum treatment duration of 28 days is usually necessary and therefore recommended. If considered successful, medication should be withdrawn for 2 weeks. If vomiting occurs again, treatment can be re-initiated without risk of intolerance. Depending on the response, treatment can be adapted to the individual animal until the response is considered to be adequate and continued. Dietary measures should always be maintained.

### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Acute exposure to cimetidine yielded LD<sub>50</sub> values above 2600 mg/kg, *i.e.* over 170 times the recommended daily dosage in dogs. A target animal safety study in dogs demonstrated that the veterinary medicinal product administered orally at 75 mg cimetidine/kg/day (five times the recommended daily dose) for a period of 91 days was well tolerated by dogs.

No signs of overdose are known.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Not applicable.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QA02BA01.**

### **4.2 Pharmacodynamics**

Cimetidine is an antagonist of the histamine H<sub>2</sub>-receptors present in the gastric parietal cells. Stimulation of H<sub>2</sub>-receptors by histamine activates gastric acid secretion. Cimetidine, via its antagonistic properties toward histamine H<sub>2</sub>-receptors, strongly reduces gastric acid secretion. This may result in the diminution of gastric irritation and subsequent vomiting during chronic gastritis. No accompanying improvement in the inflammatory status of the gastric mucosa was observed in dogs.

### **4.3 Pharmacokinetics**

After oral administration of the veterinary medicinal product at a dose rate of 5 mg/kg body weight to fasted dogs, maximal plasma levels of approximately 2 µg/ml are reached after 1.5 hours post-administration. Bioavailability is about 95%. The extent of absorption of cimetidine in dogs is delayed and reduced by approximately 40 % in the presence of food ( $C_{\max \text{ fasted}}$  2.94 mcg/ml,  $C_{\max \text{ fed}}$  1.12 mcg/ml,  $AUC_{0-\infty \text{ fasted}}$  8.23 mcg.h/ml and  $AUC_{0-\infty \text{ fed}}$  5.43 mcg.h/ml). However, this does not affect the efficacy of treatment.

The plasma half-life of cimetidine is approximately 2 hours at a dosage of 5 mg/kg. Cimetidine is rapidly and almost completely excreted into the urine. No drug accumulation occurs after repeated oral treatment at 5 mg/kg three times daily over 30 consecutive days.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Not applicable.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

### **5.3 Special precautions for storage**

Store the blisters in the original package to protect from light. Remaining tablet halves should be stored in the original blister pocket in order to protect from light.

### **5.4 Nature and composition of immediate packaging**

The tablets are packed in push-through blisters (white opaque PVC/Aluminium foil) in an outer printed carton box.

Authorised pack sizes:

Carton box containing 30 tablets (3 blister with 10 tablets per blister)

Carton box containing 100 tablets (10 blister with 10 tablets per blister)

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.

## **7. MARKETING AUTHORISATION NUMBER**

Vm 06376/5045

## **8. DATE OF FIRST AUTHORISATION**

22 February 2007

## **9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

April 2025

## **10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

*Gavin Hall*

Approved: 22 April 2025